Le Lézard
Classified in: Health
Subjects: PSF, CPG, CFG

Information Update - Health Canada warns of potential risk of pulmonary illness associated with vaping products

OTTAWA, Sept. 27, 2019 /CNW/ - Health Canada is advising Canadians who use vaping products to monitor themselves for symptoms of pulmonary illness (e.g., cough, shortness of breath, chest pain) and to seek medical attention promptly if they have concerns about their health.

In the wake of the recent cases of severe pulmonary illnesses and a number of deaths reportedly linked to the use of vaping products in the United States, Health Canada and the Public Health Agency of Canada provided national guidance to the provinces and territories on identifying cases of severe pulmonary illness related to vaping or e-cigarette use in Canada.

The Public Health Agency of Canada alerted provincial and territorial public health officials and asked them to report probable and confirmed cases in their jurisdictions.

The Province of Quebec has notified the Public Health Agency of Canada of a confirmed case of severe pulmonary illness related to vaping products. This is the first confirmed case in Canada. This follows the report out of the Middlesex-London Health Unit in Ontario of another possible case. At this time, the Middlesex-London incident is not considered confirmed as it is still under investigation and has not been officially reported to the Public Health Agency of Canada by the Province of Ontario.

Provincial and territorial health authorities are responsible for investigating possible cases. Confirmed or probable cases will be determined based on the national case definition, which was adapted for the Canadian context from the criteria set out by the United States Centers for Disease Control and Prevention (US CDC).

On August 30, the United States Food and Drug Administration (US FDA) and the US CDC released a statement on their ongoing investigation into the cause of the illnesses. The US CDC continues to provide regular updates on the investigations related to these illnesses. The source of all illnesses in the U.S. remains unclear; however, the US CDC reports that chemical exposure is the likely cause. Many patients have reported vaping tetrahydrocannabinol (THC) and/or nicotine-containing products. However, at this time, no consistent product, substance or additive has been identified in all cases.

The Government of Canada continues to monitor all available data sources and surveillance systems for signals in Canada and will take action, as appropriate. The Public Health Agency of Canada (PHAC) and the Council of Chief Medical Officers of Health have convened a federal, provincial and territorial task group on severe pulmonary illness related to vaping to develop a uniform approach to identifying and reporting cases. The Task Group is working collaboratively to develop technical documents such as a Canadian case definition; data collection tools; and information sharing processes. In addition, Health Canada has obtained samples of vaping products for testing purposes.

It is important for Canadians to know that vaping does have risks and the potential long-term effects of vaping remain unknown. Non-smokers, people who are pregnant and young people should not vape.

While no clear link has been made between any specific type or brand of vaping product and the cases of severe pulmonary illness, the Government of Canada remains deeply concerned by the increase in vaping reported among Canadian youth. Health Canada has taken a number of steps in recent months to address the rise of vaping in Canada and, in particular, the risk that it poses to youth, such as consulting on additional regulatory measures targeting promotion to youth, packaging and flavours, as well as compliance and enforcement and public awareness and youth education.

Canadians are reminded that the purchase of vaping products outside the legal market may create additional risk as these products are unregulated and potentially unsafe, and thereby pose a risk to health and safety.

Health care professionals are reminded to always ask patients, as part of their general history, whether they use drugs from any source, whether legal or illegal. When patients present with respiratory symptoms, especially if the cause is unclear, health care professionals should ask about the use of vaping products, including electronic cigarette (e-cigarette) products,?such as devices, liquids, refill pods and/or cartridges.

What is vaping?

Vaping is the act of inhaling and exhaling an aerosol produced by a vaping product, such as an ecigarette. Vaping doesn't require burning the way cigarette smoking does. The device heats a liquid into a vapour, which then turns into an aerosol. This vapour can contain substances such as nicotine and flavourings.

Vaping devices are usually battery-powered. They may come with removable parts. Vaping products have many names, including:

They may also be known by various brand names. More information about vaping is available on Health Canada's website.

Cannabis vaping

Cannabis can be consumed in different ways, including by vaporizing and vaping (breathing in dried cannabis or liquid cannabis vapors through a vaporizer or vaping device). Illegal cannabis, including cannabis vaping products that are sold on the illegal market, are not quality-controlled and may be contaminated.

What you should do

Également disponible en français 

SOURCE Health Canada

These press releases may also interest you

at 10:20
Report Scope: The current report provides detailed exposure to blockchain technology in healthcare industry.This report also highlights current and future market potential of blockchain technology along with a detailed analysis of the competitive...

at 10:17
Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today announced an anticipated increase in gross margins from the consolidation of its business structure and focus on its Cannabis Biopharmaceutical Technology.  KALY...

at 10:15
The global market for Stem Cell Banking is projected to reach US$9. 9 billion by 2025, driven by their growing importance in medicine given their potential to regenerate and repair damaged tissue. Stem cells are defined as cells with the potential to...

at 10:07
Pearl today announced two new breakthrough software products in the application of artificial intelligence and computer vision to dental insurance claims processing. Together, Pearl's new AI solutions represent a massive leap forward for dental...

at 10:05
The "Drug of Abuse Testing Market (By Product Type, Sample/Test Type, End Users / Setting Type, Region), Regulatory Status, 20 Company Profiles - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering. The use of...

at 10:03
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation , announced that it has received the 2019 Best of...

News published on 28 september 2019 at 10:00 and distributed by: